Investigating the Role of JAK/STAT Pathway on Dasatinib-Induced Apoptosis for CML Cell Model K562.

Dalgic C. , Kaymaz B. , Ozkan M. C. , Dalmizrak A., Şahin F. , Saydam G.

Clinical lymphoma, myeloma & leukemia, 2015 (Journal Indexed in SCI Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume:
  • Publication Date: 2015
  • Doi Number: 10.1016/j.clml.2015.02.012
  • Title of Journal : Clinical lymphoma, myeloma & leukemia
  • Keywords: Apoptosis, Chronic myeloid leukemia, Dasatinib, JAK/STAT pathway, STAT5, CHRONIC MYELOID-LEUKEMIA, CHRONIC-PHASE, ACTIVATION, PROTEINS, STAT5


We aimed to evaluate the cytotoxic and apoptotic effects of dasatinib (BMS-354825) on K562 chronic myeloid leukemia (CML) cells and to examine the roles of STAT genes on dasatinib-induced apoptosis. The results showed that dasatinib decreased proliferation and induced apoptosis in K562 cells in a dose- and time-dependent manner. mRNA and protein levels of STAT5A and STAT5B genes were significantly reduced in dasatinib-treated K562 cells. These data indicated that STAT inhibition by dasatinib might be therapeutic in JAK/STAT pathway associated malignancies after confirmation with clinical studies. (C) 2015 Elsevier Inc. All rights reserved.